[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR050273A1 - Derivados de tiofeno como agentes inmunosupresores - Google Patents

Derivados de tiofeno como agentes inmunosupresores

Info

Publication number
AR050273A1
AR050273A1 ARP050103142A ARP050103142A AR050273A1 AR 050273 A1 AR050273 A1 AR 050273A1 AR P050103142 A ARP050103142 A AR P050103142A AR P050103142 A ARP050103142 A AR P050103142A AR 050273 A1 AR050273 A1 AR 050273A1
Authority
AR
Argentina
Prior art keywords
alkoxy
alkyl
hydroxy
case
ch2nh
Prior art date
Application number
ARP050103142A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR050273A1 publication Critical patent/AR050273A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente se refiere a derivados de tiofeno, a su preparacion y a su uso como compuestos farmacéuticamente activos. Dichos compuestos actuan en particular como agentes inmunosupresores. Reivindicacion 1: Un compuesto seleccionado del grupo que consiste en tiofenos de la formula (1), en la que: A representa -CH2CH2-, -CH=CH-, -NH-CH2-, -CH2-O- o -CH2NH-; R1 representa hidrogeno o alquilo; en el caso de que X represente C-R4, R1 representa, además, halogeno; y en el caso de que A represente -CH2-CH2- o -CH2NH-, R1 representa, además, alcoxi; R2 representa hidrogeno, alcoxi, fluor-alcoxi, hidroxi-alcoxi, hidroxi-alquilo, di-(hidroxi-alquil)-alquilo, di-(hidroxi-alquil)-alcoxi, 1-glicerilo, 2-glicerilo, piridin-3-il-metoxi- o piridin-4-il-metoxi; R3 representa hidrogeno, alquilo, mono- o di-alquilamino, trifluormetilo o trifluormetoxi; en el caso de que X represente C-R4, R3 representa, además, halogeno; y en el caso de que A represente -CH2-CH2- o -CH2NH-, R3 representa, además, alcoxi; X representa N o C-R4; R4 representa hidrogeno, alquilo, alcoxi o halogeno; y R5 representa metilo o etilo; y enantiomeros opticamente puros, mezclas de enantiomeros tales como racematos, diastereomeros, mezclas de diastereomeros, racematos diastereoméricos y mezclas de racematos diastereoméricos, así como también sales y solventes de dichos compuestos, y formas morfologicas.
ARP050103142A 2004-07-29 2005-07-28 Derivados de tiofeno como agentes inmunosupresores AR050273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2004/008501 WO2006010379A1 (en) 2004-07-29 2004-07-29 Novel thiophene derivatives as immunosuppressive agents

Publications (1)

Publication Number Publication Date
AR050273A1 true AR050273A1 (es) 2006-10-11

Family

ID=34958296

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103142A AR050273A1 (es) 2004-07-29 2005-07-28 Derivados de tiofeno como agentes inmunosupresores

Country Status (23)

Country Link
US (1) US7750040B2 (es)
EP (1) EP1805163B1 (es)
JP (1) JP4807884B2 (es)
KR (1) KR20070046849A (es)
CN (1) CN1993346B (es)
AR (1) AR050273A1 (es)
AT (1) ATE409697T1 (es)
AU (1) AU2005266529A1 (es)
BR (1) BRPI0513841A (es)
CA (1) CA2574305A1 (es)
DE (1) DE602005010109D1 (es)
DK (1) DK1805163T3 (es)
ES (1) ES2313391T3 (es)
IL (1) IL180962A0 (es)
MX (1) MX2007000972A (es)
NO (1) NO20071095L (es)
PL (1) PL1805163T3 (es)
PT (1) PT1805163E (es)
RU (1) RU2386626C2 (es)
SI (1) SI1805163T1 (es)
TW (1) TW200616994A (es)
WO (2) WO2006010379A1 (es)
ZA (1) ZA200700535B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4678139B2 (ja) * 2004-05-10 2011-04-27 トヨタ自動車株式会社 自動車の暖房制御システム
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
US7241812B2 (en) 2004-08-13 2007-07-10 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
KR20080002850A (ko) * 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
ATE510831T1 (de) * 2005-03-23 2011-06-15 Actelion Pharmaceuticals Ltd Hydrierte benzoäcüthiophenderivate als immunmodulatoren
JP5072825B2 (ja) 2005-03-23 2012-11-14 アクテリオン ファーマシューティカルズ リミテッド スフィンゴシン−１−ホスフェート−１受容体アゴニストとしての新規チオフェン誘導体
WO2006137019A1 (en) * 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
AR057894A1 (es) * 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
EP1979345B1 (en) 2006-01-24 2009-11-04 Actelion Pharmaceuticals Ltd. Novel pyridine derivatives
AR061841A1 (es) * 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
DK2069336T3 (da) * 2006-09-07 2013-02-25 Actelion Pharmaceuticals Ltd Pyridin-4-yl-derivater som immunomodulerende midler
NZ576059A (en) * 2006-09-08 2012-03-30 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
DE102007019677A1 (de) 2006-11-06 2008-05-08 Carl Zeiss Surgical Gmbh Operationsmikroskop mit OCT-System und Operationsmikroskop-Beleuchtungsmodul mit OCT-System
DE102007019680A1 (de) 2006-11-06 2008-05-08 Carl Zeiss Surgical Gmbh Ophthalmo-Operationsmikroskop mit OCT-System
DE102007019679A1 (de) 2006-11-06 2008-05-15 Carl Zeiss Surgical Gmbh Operationsmikroskop mit OCT-System
ES2450750T3 (es) * 2007-03-16 2014-03-25 Actelion Pharmaceuticals Ltd. Derivados de amino-piridina como agonistas del receptor S1P1/EDG1
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
BRPI0820868A2 (pt) * 2007-12-10 2019-09-24 Actelion Pharmaceuticals Ltd composto de tiofeno fórmula(i), composição farmacêutica contendo o mesmo e uso deste para a prevenção ou tratamento de doenças ou disturbíos associados a um sistema imune ativado
WO2009074969A2 (en) * 2007-12-12 2009-06-18 University Of Lausanne Sphingosine-1-phosphate, analogs and antagonists for use as medicaments
JP5411877B2 (ja) * 2008-03-06 2014-02-12 アクテリオン ファーマシューティカルズ リミテッド ピリジン化合物
KR101615779B1 (ko) * 2008-03-07 2016-04-26 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-2-일 유도체
US8785484B2 (en) 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
WO2010006704A1 (en) 2008-07-15 2010-01-21 Sanofi-Aventis Oxazolopyrimidines as edg-1 receptor agonists
NZ590474A (en) 2008-07-23 2012-10-26 Arena Pharm Inc SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
WO2010027431A1 (en) 2008-08-27 2010-03-11 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
DE102009002514A1 (de) 2009-04-21 2010-10-28 Evonik Degussa Gmbh Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden
PT2454255E (pt) 2009-07-16 2014-01-14 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agonistas de s1/p1/edg1
KR20170072358A (ko) * 2009-08-28 2017-06-26 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
JP2013521301A (ja) 2010-03-03 2013-06-10 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体修飾物質およびその結晶形の調製のためのプロセス
TWI546300B (zh) 2011-01-19 2016-08-21 艾克泰聯製藥有限公司 ２－甲氧基－吡啶－４－基衍生物
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CN104540800B (zh) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
DE102013208091B4 (de) 2013-05-02 2019-05-09 Carl Zeiss Ag Vorrichtung und Verfahren zum Vermessen einer Flächentopografie
DE102014222629A1 (de) 2014-11-05 2016-05-12 Carl Zeiss Meditec Ag Untersuchen eines Objekts mit OCT-Abtastlichtstrahlen
DE202014011051U1 (de) 2014-11-05 2017-07-26 Carl Zeiss Meditec Ag Vorrichtung für das Untersuchen eines Patientenauges
DE202014011050U1 (de) 2014-11-05 2017-07-26 Carl Zeiss Meditec Ag Vorrichtung für das Untersuchen eines Patientenauges
NZ771435A (en) 2015-01-06 2024-08-30 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
PL3298008T3 (pl) 2015-05-20 2020-05-18 Idorsia Pharmaceuticals Ltd Krystaliczna postać związku, (S)-3-{4-[5-(2-cyklopentylo-6-metoksypirydyn-4-ylo)-[1,2,4]oksadiazol-3-ilo]-2-etylo-6-metylofenoksy}propano-1,2-diolu
US10111841B2 (en) 2015-06-19 2018-10-30 University Of South Florida Stabilization of alcohol intoxication-induced cardiovascular instability
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
CN113072519A (zh) * 2021-04-01 2021-07-06 福建海西新药创制有限公司 一种利用微反应装置连续生产非布司他的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2599740B1 (fr) 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
US4963557A (en) 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
AU653957B2 (en) 1990-09-20 1994-10-20 Merrell Dow Pharmaceuticals Inc. 1-aryl-3-pyridinyl-2-propene-1-ones
EP1070080A4 (en) 1998-03-09 2004-12-29 Smithkline Beecham Corp HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND THEIR APPLICATIONS
GB9808665D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic compounds
DE60208683T2 (de) 2001-08-01 2006-11-02 Basell Polyolefine Gmbh Verfahren zur herstellung von heterocyclischen pentalen derivaten
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
US20040058894A1 (en) * 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
EP1549640A4 (en) 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
EP1546110A4 (en) 2002-07-30 2008-03-26 Univ Virginia ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
CA2539438A1 (en) 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2005058848A1 (en) 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
ATE510831T1 (de) 2005-03-23 2011-06-15 Actelion Pharmaceuticals Ltd Hydrierte benzoäcüthiophenderivate als immunmodulatoren
KR20080002850A (ko) 2005-03-23 2008-01-04 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
JP5072825B2 (ja) 2005-03-23 2012-11-14 アクテリオン ファーマシューティカルズ リミテッド スフィンゴシン−１−ホスフェート−１受容体アゴニストとしての新規チオフェン誘導体
CA2610310A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
WO2006137019A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
US20080005421A1 (en) 2006-05-19 2008-01-03 Chi-Tung Chang Switching Device of Input and Output Interfaces of Computer Systems
KR20090095648A (ko) 2006-12-15 2009-09-09 아보트 러보러터리즈 신규한 옥사디아졸 화합물
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds

Also Published As

Publication number Publication date
US7750040B2 (en) 2010-07-06
MX2007000972A (es) 2007-04-10
RU2007107164A (ru) 2008-09-10
ES2313391T3 (es) 2009-03-01
NO20071095L (no) 2007-02-27
JP2008508210A (ja) 2008-03-21
SI1805163T1 (sl) 2009-02-28
KR20070046849A (ko) 2007-05-03
ATE409697T1 (de) 2008-10-15
EP1805163B1 (en) 2008-10-01
DE602005010109D1 (de) 2008-11-13
PT1805163E (pt) 2008-12-05
JP4807884B2 (ja) 2011-11-02
TW200616994A (en) 2006-06-01
DK1805163T3 (da) 2008-12-15
CN1993346B (zh) 2011-04-27
EP1805163A2 (en) 2007-07-11
WO2006010379A1 (en) 2006-02-02
CA2574305A1 (en) 2006-02-02
WO2006010544A2 (en) 2006-02-02
WO2006010544A3 (en) 2006-03-30
US20080064740A1 (en) 2008-03-13
CN1993346A (zh) 2007-07-04
BRPI0513841A (pt) 2008-05-20
ZA200700535B (en) 2008-10-29
PL1805163T3 (pl) 2009-04-30
IL180962A0 (en) 2007-07-04
RU2386626C2 (ru) 2010-04-20
AU2005266529A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
AR050273A1 (es) Derivados de tiofeno como agentes inmunosupresores
AR057894A1 (es) Derivados de tiofeno
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
CR9980A (es) Imidazolinas 4,4,5,5 tetrasustituidas
MY137133A (en) Novel compounds
UY29449A1 (es) Tratamiento de enfermedades dermatólogicas y del prurito.
MY143400A (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
RS53673B1 (en) FUNGICID MIXTURES CONTAINING SUBSTITUTED ANILIDES 1-METHYL-PIRAZOL-4-IL CARBOXYLIC ACIDS
UY27388A1 (es) Nuevos compuestos
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
ECSP088184A (es) Derivados de benzoquinazolina y su uso en el tratamiento de enfermedades óseas
AR034259A1 (es) Polimorfos de un analogo de epotilona, procesos para prepararlos y las composiciones farmaceuticas que los contienen
ECSP034849A (es) Sales tartrato de 5, 8, 14-triazatetraciclo [10.3.1.02,11.04,9] hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
UY30527A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
HRP20070577T4 (hr) Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
SE0302487D0 (sv) Novel compounds
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP066588A (es) Tiazolidinonas, su preparación y su uso como medicamentos
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
RS51521B (en) USE OF BENZO-FUZIONIZED HETEROCYCLIC SULFAMIDE DERIVATIVES FOR LIPID DISORDER AND BLOOD GLUCOSE CONTENT
AR055431A1 (es) Derivados del acido 4-amino-tieno[3,2-c]piridina-7-carboxilico
AR047382A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal